TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications to older adults. It applies the Geriatrics 5Ms to GLP-1 medications and incretin therapy, and highlights assessment of function, nutrition and cognition, with attention to frailty, muscle loss, malnutrition and dehydration.
The American Geriatrics Society (AGS) has published a case-based framework on patient-centered prescribing of obesity medications for older adults. The paper applies the Geriatrics 5Ms to incretin therapy, including GLP-1 medications, and recommends assessing function, nutrition and cognition before treatment. It also recommends considering resistance training and adequate dietary protein.
Published in the Journal of the American Geriatrics Society, the paper was developed by the AGS Healthy Aging Special Interest Group. It presents clinical cases and applies the 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapy.
The paper says clinicians should carefully consider age-related factors, including frailty, sarcopenia and loss of lean muscle, as well as malnutrition and dehydration. It recommends reviewing patients’ functional status, nutritional adequacy and cognitive impairment before starting treatment.
The authors recommend considering resistance exercise and adequate dietary protein. For some patients, care may involve a team such as a registered dietitian, physical therapist, fitness trainer and behavioral health professional.
Balancing Weight Treatment and Function
The report discusses obesity medications in relation to weight management and glycemic control. It also recommends assessing functional status and considering age-related factors, including nutrition and muscle loss, when prescribing for older adults.
The authors say older adults are underrepresented in clinical trials of these medications. The paper applies the Geriatrics 5Ms—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapy in older adults.
The authors also recommend considering resistance exercise and adequate dietary protein. For some patients, they describe possible team-based care involving nutrition, physical therapy, fitness or behavioral health professionals.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Bowflex SelectTech 840 Adjustable Kettlebell
Levoit Core 400S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
The Geriatrics 5Ms in Prescribing
The paper applies five areas—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapy. It presents the framework through clinical cases and describes it as a practical approach to prescribing obesity medications for older adults.
The report notes that older people have been underrepresented in clinical trials of these medications. Published in October 2026, the paper discusses how the 5Ms apply to prescribing decisions involving older adults.
“Older adults are underrepresented in clinical trials.”
— Medical Xpress report describing the AGS framework
Evidence Gaps in Older Patients
The source material does not give detailed trial results, patient numbers or estimates of how often older adults experience muscle loss, malnutrition or dehydration while using these drugs. It also does not specify which medication, dose or patient profile should be preferred under the framework. Those questions cannot be answered from the report alone.
The paper is described as a clinical framework, not evidence that its approach has been tested against usual care or has improved health outcomes. The source also does not set out a complete monitoring schedule or define how clinicians should weigh each 5M when priorities conflict. Individual decisions remain dependent on clinical assessment and discussion with the patient.
Applying the Framework in Care
The framework is available through the Journal of the American Geriatrics Society paper, which clinicians can use to guide case discussions and prescribing assessments. The source does not announce a rollout, implementation deadline or planned follow-up study. Whether the approach changes prescribing practice or patient outcomes remains to be established.
For patients considering obesity medication, the report points to topics to raise with a clinician: baseline function and nutrition, muscle-strengthening activity, protein intake, hydration, other medicines and personal treatment goals. Any decision to start or change a medication should be made with a qualified healthcare professional who can evaluate the patient’s circumstances.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians prescribing obesity medications to older adults, applying the Geriatrics 5Ms to incretin therapies.
Which factors does the framework ask clinicians to assess?
It recommends pretreatment assessment of functional status, nutritional adequacy and cognition, with attention to frailty, sarcopenia, muscle loss, malnutrition and dehydration.
Does the framework advise stopping obesity medications in older adults?
No. The source describes guidance for safe, patient-centered prescribing; it does not call for stopping treatment or say that the medications are unsuitable for all older adults.
What support may accompany medication treatment?
The authors recommend considering resistance training and adequate dietary protein. Some patients may benefit from team-based support involving nutrition, physical therapy, fitness or behavioral health professionals.
Has the framework been shown to improve outcomes?
The source does not report an outcomes trial testing the framework. It presents a clinical decision-making approach, and its effects on prescribing or patient health are not established by the report.
Source: medicalxpress.com
